Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.46 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | IGF1R | P08069 | 2/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL414898 | 0.94 | NEK1 (0.47) | RIPK1NEK1AAK1KITAXL | |
| SCHEMBL858392 | 0.88 | AAK1 (0.46) | RIPK1NEK1AAK1KITPLCG1 | |
| SCHEMBL856312 | 0.87 | RIPK1 (0.45) | RIPK1NEK1AAK1 | |
| SCHEMBL10260876 | 0.86 | RIPK1 (0.45) | RIPK1NEK1AAK1PLCG1DYRK1A | |
| SCHEMBL859227 | 0.85 | GSK3B (0.49) | RIPK1NEK1AAK1PLCG1DYRK1A | |
| SCHEMBL10260007 | 0.85 | RIPK1 (0.44) | RIPK1NEK1AAK1 | |
| SCHEMBL417056 | 0.84 | AAK1 (0.43) | RIPK1NEK1AAK1AXLDYRK1A | |
| SCHEMBL10261619 | 0.84 | RIPK1 (0.49) | RIPK1NEK1AAK1PLCG1DYRK1A | |
| SCHEMBL857629 | 0.83 | DYRK1A (0.47) | RIPK1NEK1AAK1KITAXL | |
| SCHEMBL855708 | 0.81 | PIK3CA (0.43) | RIPK1NEK1AAK1KITDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059963-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | RIPK1 507/4885NEK1 223/4885AAK1 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.